Medical Oncology Vol. III
Four topics, 47 cases — choose one below to browse its cases.
Oncologic emergencies (hypercalcemia, spinal cord compression, febrile neutropenia, SVC syndrome, cancer-associated VTE), treatment-related toxicity management (neutropenia prophylaxis, immune-related colitis, chemotherapy-induced neuropathy), cancer pain and opioid rotation, fertility preservation and secondary-cancer-risk chemoprevention, and end-of-life decision-making
Melanoma immunotherapy sequencing and toxicity management, BRAF-targeted and KIT-directed therapy selection, basal cell and squamous cell carcinoma pharmacology (including transplant-recipient immunosuppression tradeoffs), Merkel cell and sarcoma histology-driven regimen selection, and biomarker-directed therapy in cancer of unknown primary
Glioma and CNS lymphoma pharmacology, brain metastasis management (radiosurgery vs. systemic-therapy switching), head and neck cancer regimen selection and de-escalation decisions, and thyroid cancer targeted-therapy selection across differentiated, medullary, and anaplastic subtypes
Ovarian cancer maintenance and sequencing decisions (PARP inhibitors, bevacizumab, MEK inhibitors), cervical cancer therapy selection, endometrial cancer biomarker-directed therapy, hereditary-risk surgical timing, and gestational trophoblastic neoplasia risk scoring